Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience
- 13 September 2023
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 383, 578199
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and TreatmentViruses, 2022
- Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responsesFrontiers in Immunology, 2022
- Antibody Response to COVID-19 Booster Vaccination in Healthcare WorkersFrontiers in Immunology, 2022
- Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depletersMultiple Sclerosis and Related Disorders, 2022
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19New England Journal of Medicine, 2022
- Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With OcrelizumabJAMA Neurology, 2021
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapyNature Medicine, 2021
- Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disordersJournal of Neurology, Neurosurgery & Psychiatry, 2021
- DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and FranceAnnals of Clinical and Translational Neurology, 2021
- Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisAnnals of Neurology, 2021